Prostate Health Index (phi score, 4Kscore®, MiCheck®, ClarityDX Prostate), Serum
Prostate Health Index (phi) is an algorithm based FDA approved test used for early detection of prostate cancer in patients with elevated PSA between 4-12ng/mL. This test has better specificity compared to prostate biopsy and can be used as a tool for biopsy decision. The Prostate Health Index is a calculation of three blood tests; Prostate Specific Antigen (PSA), Free Prostate Specific Antigen (fPSA) and Pro-Prostate Specific Antigen also know as [-2]proPSA (P2PSA) to produce a “phi” score. Increase in phi score indicates an increased risk of prostate cancer which may lead to biopsy for further evaluation for prostate cancer. The specificity of this test is based on measuring P2PSA which has two extra amino acids relative to mature PSA. The P2PSA biomarker is an isoform of free PSA that was identified as the most prostate cancer-specific form found in prostate tumor extracts. It has been shown that increased levels of P2PSA is strongly associated with prostate cancer and cancer progression; however, the best utility is in conjunction with total and free PSA as used in phi.
Another developed test for rule-out prostate biopsy is the 4Kscore® Test. The 4Kscore® Test is indicated for use in men 45 years of age and older who have an abnormal age-specific total PSA and/or abnormal DRE, prior to the first biopsy or after a negative biopsy, and in combination with other patient information as an aid in the decision for prostate biopsy. The 4Kscore® Test combines four prostate-specific biomarkers (Total PSA, Free PSA, Intact PSA, and human kallikrein 2 [hK2]) with important clinical factors (age, prior biopsy status, and DRE) to provide a man’s probability of finding high-grade, aggressive prostate cancer. A 4Kscore® <5.0 is associated with decreased likelihood of a Gleason score ≥7 on biopsy. Prostate biopsy is required for the diagnosis of cancer. The test is not recommended more than once every 6 months.
MiCheck® Prostate is an algorithm that combines the testing results of three Abbott ARCHITECT™ serum immunoassays (total prostate specific antigen (tPSA), free PSA (fPSA) and Human Epididymal Protein 4 (HE4)) and one clinical factor (i.e. the patient’s Age). The MiCheck® Prostate algorithm combines these results to calculate a Percentage Risk Score, which provides an indication of the likelihood of the presence of clinically significant Prostate Cancer (csPCa) (Gleason score >3+4) and is called the MiCheck® %Risk of csPCa. MiCheck® Prostate is indicated for male subjects being considered by physicians for a prostate biopsy. It is intended to supplement and not replace the significance of other clinical factors or test results which collectively assist the clinical judgement and experience of the urologist in the decision about whether or not to proceed to prostate biopsy. Prostate biopsy is required for the diagnosis of cancer. The MiCheck® Prostate test is intended for professional use only. MiCheck® Prostate test is currently offered as a Laboratory Developed Test (LDT) to urologists and clinicians. The three immunoassays are performed by qualified high complexity CLIA laboratories which have validated the test to generate MiCheck® Prostate % Risk of csPCa for the MiCheck® Prostate Physician’s report.
ClarityDx Prostate, is a blood test that determines the risk of prostate cancer up to 4x more accurately than PSA alone, for men with clinical suspicion of prostate cancer. ClarityDx Prostate is a decision support tool that provides a risk score based on clinical and biological biomarkers. It helps patients at risk of prostate cancer make informed decisions about the need for prostate biopsy.
Prostate cancer is a leading cause of cancer mortality in men. The currently approved screening test for prostate cancer in both symptomatic and asymptomatic men is serum PSA. Typically, an elevated PSA would be followed by prostate biopsy to confirm the presence of prostate cancer, and treatment would be based on the results of the biopsy. Since PSA is not a specific to prostate cancer and can be elevated in other prostate disorders such as prostatitis, nonmalignant enlargement of the prostate (known as benign prostatic hyperplasia or BPH), increase levels of PSA can non-specifically lead to unnecessary prostate biopsies and overtreatment of presumed prostate cancer. Therefore, using phi score may improve specificity of and elevated PSA in determining the need for biopsy.
- As a secondary test for early detection of prostate cancer in patient with elevated PSA between 4-12ng/mL
- As an aid in biopsy decision; simply to avoid negative biopsies in patient with BPH or other prostate disorders that are not considered cancerous
- As an aid in the decision for prostate biopsy in men 45 years of age and older who have an abnormal age-specific total PSA and/or abnormal DRE
- Differential diagnosis of prostate cancer from other benign prostate conditions
Low phi indicates lower probability of finding prostate cancer on biopsy and higher phi scores are associated with an increased probability of finding prostate cancer on biopsy. The choice of an appropriate phi score to be used in guiding clinical decision-making may vary for each patient and may depend on other clinically factors or on family history of disease. The table under reference ranges indicates the probability of finding prostate cancer on biopsy when PSA is the in range of 4 to 10 ng/mL and may be used as guidance for interpreting the phi score.
A 4Kscore® <5.0 is associated with decreased likelihood of a Gleason score ≥7 on biopsy. Prostate biopsy is required for the diagnosis of cancer. The test is not recommended more than once every 6 months.
| phi Range* | Probability of Cancer | 95% Confidence Interval |
| 0-26.9 | 9.8% | 5.2%-15.4% |
| 27.0-35.9 | 16.8% | 11.3%-22.2% |
| 36.0-54.9 | 33.3% | 26.8%-39.9% |
| 55.0+ | 50.1% | 39.8%-61.0% |
4Kscore®: <5.0
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (Red top tube).
Stability
- Ambient: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 1 month
- Clin Chem Lab Med 2013;51(4):729-39. [PMID: 23154423]
- Urol Oncol. 2021 Jun;39(6):366.e1-366.e10. [PMID: 33685800]
- J Urol 2011;185(5):1650-5. [PMID: 21419439]
- Urology. 2021 Feb;148:53-58. doi: 10.1016/j.urology.2020.11.008. [PMID: 33217456]
- Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19. [PMID: 27922627]
- Clin Chem 2013;59(1):306-14. [PMID: 23213080]
- Health Technol Assess. 2015 Oct;19(87):i-xxxi, 1-191. [PMID: 26507078]
- Clin Chem 2004;50(6):1017-25. [PMID: 15054080]
- Cancer Epidemiol Biomarkers Prev 2010;19(5):1193-200. [PMID: 20447916]
- Nat Rev Cancer 2008;8(4):268-78. [PMID: 18337732]
- JAMA 1998;279(19):1542-7. [PMID: 9605898]
- Fauci AS, Braunwald E, Kasper DL, et al.Harrison's Principles of Internal Medicine. McGraw-Hill Professional. 2004.